SK Acquires BMS Irish Plant To Support Global CMO Leadership Ambitions

SK Biotek's acquisition of BMS's small molecule API manufacturing plant in Ireland underlines South Korean conglomerate SK Group’s stepped up efforts to grow its biotech and pharma business. The move is in line with SK Biotek's plan to sharply raise revenue and corporate value in the coming years, and the CMO is also considering additional acquisitions or collaborations.

Business teamwork puzzle pieces.

SK Biotek Co. Ltd. has reached a definitive agreement to buy Bristol-Myers Squibb Co.’s small molecule active pharmaceutical ingredient (API) manufacturing facility in Swords, Ireland, as part of its plan to boost production capacity and have a production base in Europe to help a planned transformation into a leading global contract manufacturing organization.

"This will be our first overseas manufacturing plant. We are aiming to sharply raise revenue and corporate value by 2020,...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip